Bartz S R, Hohenwalter E, Hu M K, Rich D H, Malkovsky M
Department of Medical Microbiology and Immunology, University of Wisconsin, Madison 53706, USA.
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5381-5. doi: 10.1073/pnas.92.12.5381.
Analogs of the immunosuppressive cyclic undecapeptide cyclosporin A (CsA) with substitutions in positions 1, 4, 6, and/or 11 were rationally designed to possess substantially diminished or no immunosuppressive activity. When these compounds were assayed for their capacity to interfere with the replication of human immunodeficiency virus, some displayed a potent antiviral activity in newly infected cells. However, only CsA could interfere with virus replication in persistently infected cells. One CsA analog with antiviral activity costimulated the phytohemagglutinin-induced production of interleukin 2 by human lymphocytes. Human immunodeficiency virus particles from drug-exposed cells showed lower infectivity than virions from untreated cells. Thus, these nonimmunosuppressive analogs of CsA constitute a promising class of lead compounds to develop drugs for effective treatment of the acquired immunodeficiency syndrome.
对免疫抑制性环十一肽环孢素A(CsA)在第1、4、6和/或11位进行取代的类似物进行了合理设计,使其免疫抑制活性大幅降低或无免疫抑制活性。当检测这些化合物干扰人类免疫缺陷病毒复制的能力时,一些化合物在新感染的细胞中表现出强大的抗病毒活性。然而,只有CsA能够干扰持续感染细胞中的病毒复制。一种具有抗病毒活性的CsA类似物共刺激了植物血凝素诱导的人淋巴细胞白细胞介素2的产生。来自药物处理细胞的人类免疫缺陷病毒颗粒的感染性低于未处理细胞的病毒体。因此,这些CsA的非免疫抑制类似物构成了一类有前景的先导化合物,可用于开发有效治疗获得性免疫缺陷综合征的药物。